As part of its response to the COVID-19 pandemic, Teva Canada has secured a four-week supply of Salamol (salbutamol) 100mcg 200-dose inhalers through its global supply chain, from Teva UK, in order to mitigate shortages in the Canadian market.
Teva, Sandoz And Accord Take COVID-19 Action
Apotex Donates Critical Medicines, MedPharm Screens And Beximco Focuses Efforts
While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic effectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.
More from Generics
More from Products
• By
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
• By
With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.
• By
As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.